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Aggressive lymphomas can present with symptoms mimicking life-threatening infection. Flow cytometry (FC) is usually rec-
ommended for the classiﬁcation and staging of lymphomas in patients with organomegaly and atypical cells in eﬀusions and
blood, after the exclusion of other possible diagnoses. FC may also have a place in the initial diagnostic investigation of
aggressive lymphoma. Three cases are presented here of highly aggressive lymphomas in young adults, which presented with
the clinical picture of fever of unknown origin (FUO) in patients severely ill. All followed a life-threatening clinical course, and
two developed the hemophagocytic syndrome (HPS), but microbiological, immunological, and morphological evaluation and
immunohistochemistry (IHC) failed to substantiate an early diagnosis. FC was the technique that provided conclusive diagnostic
evidence of lymphoma, subsequently veriﬁed by IHC. Our experience with these three cases highlights the potential role of FC as
anadjunct methodology in the initialassessmentofpossible highly aggressive lymphomapresenting with the signs and symptoms
of life-threatening infection, although the deﬁnitive diagnosis should be established by biopsy. In such cases, FC can contribute to
the diagnosis of lymphoma, independently of the presence of HPS.
1.Introduction
Theclinicalindicationsforﬂowcytometry(FC)arechanging
with the documentationofnew evidence.The Bethesda 2006
Consensus decided on a list of clinical indications for FC [1],
which include staging of disease, prognostic and therapeutic
purposes, and monitoring of disease progress, but the use
of FC in the initial assessment of life-threatening clinical
situations, such as highly aggressive lymphoma, has not been
evaluated. Lymphomas are seriously considered in the diﬀer-
ential diagnosis of patients presenting with persistent fever
of unknown origin (FUO) [2, 3], although the exclusion of
an infectious cause is of major priority. The hemophagocytic
syndrome (HPS), or hemophagocytic lymphohistiocyto-
sis (HLH), can be associated with a variety of infections,
autoimmunediseases,andcongenitaldisorders,butalsowith2 Case Reports in Medicine
lymphomas [4]. In cases of life-threatening infection with or
without HPS, FC could possibly have an adjuvant diagnostic
role in the initial assessment.
In this paper, we present three cases which ultimately
provedtobeaggressivelymphomas,butallthreeinitiallypre-
sented as life-threatening infections with no evidence of an
infectiouscausativeagent,andtwowereassociatedwithHPS.
Our main purpose is to highlight the role of FC as an initial
diagnostic tool in the assessment of such cases, in which
a deﬁnitive diagnosis is urgently required. FC can provide
strong evidence of lymphoma, but the ﬁnal diagnosis should
always be established by biopsy.
2.CaseSeriesPresentation
2.1. Case 1
2.1.1. Clinical Course. A 34-year-old male was admitted for
the investigation of a 4-day fever and fatigue, accom-
panied by painful right inguinal lymphadenopathy and
hepatosplenomegaly. During the ﬁrst 2 weeks of hospi-
talization, the patient’s condition deteriorated (Table 1),
with the development of pleural eﬀusion and hepatic and
renal failure. The diagnosis of an infectious disease was
strongly suspected, but cultures (from urine, blood, sputum,
stool, and lymph node) and extensive investigation for
viruses and other infectious agents were negative (Table 1).
There was no clinical response to the administration of
multiple antibiotics. FC analysis of the peripheral blood 20
days after admission, following the observation of atypical
cells, was suspicious for a T-anaplastic lymphoma variant,
and lymph node biopsy conﬁrmed the FC ﬁndings. The
Karyotype was normal and TCR rearrangements were neg-
ative.
2.1.2. Morphology. Morphological examination of periph-
eral blood smear detected 30% atypical lymphocytes with
irregular,eccentric,kidney-shaped,andinclusion-likenuclei,
but also 2-3% rare large cells, with dispersed nuclear
chromatin and basophilic microvacuolated cytoplasm,. The
lymph node biopsy showed 20–30% large- and medium-
sized cells with nucleoli and basophilic cytoplasm with small
vacuoles. The other lymphocytes were small, with mature
chromatin.
2.1.3. FC. Peripheral blood FC showed similar ﬁndings to
the lymph node FC analysis, on which the ﬁnal diagnosis
was based (Table 2). An atypical lymphocytic population of
T-origin was detected, cCD3 brightly positive, CD2 positive,
but negative for CD3, Tdt, TCRαβ,T C R γδ and CD5. An-
tigens of B and NK origin were absent, and Ki-67, as a
marker of proliferation rate, was increased. CD25 was
negative (regarding the possibility of an adult T-cell/leuke-
mia/lymphoma), while the expression of CD30 and EMA,
with concurrent absence of CD15, suggested a T-anaplastic
non-Hodgkin lymphoma (NHL), Ki-1(CD30)+, small cell
variant,which rarelypresentswithleukemicpictureandwith
large, vacuolated, basophilic cells.
2.1.4. Immunohistochemistry (IHC). IHC examination of
bone marrow (BM) aspirate was not diagnostic, but lymph
node processing revealedthe diagnosis of amalignant diﬀuse
NHL of T-origin (CD2+, UCHL-1+), with small- and me-
dium-sized atypical cells, with CD30+, suggesting a T-an-
aplastic CD30+ lymphoma, small cell variant.
2.1.5. Outcome. Although treatment was delayed because of
the delay in diagnosis, a complete remission was achieved.
2.2. Case 2
2.2.1. Clinical Course. A 47-year-old male was admitted for
the investigation of a 40-day FUO, with fatigue, weight loss,
anemia, and thrombocytopenia. He had been hospitalized
in another hospital, where no diagnosis was documented.
His past medical history included chronic hepatitis B-virus
infection, and heterozygosity for β-thalassemia. During hos-
pitalization, the persistence ofthe feverand the development
of a pericardial eﬀusion and acute renal and respiratory
failure indicated an infectious etiology. A. baumannii and S.
epidermidis were isolated in blood cultures, but an extensive
microbiological and immunological workup revealed no
causative infectious agent (Table 1), and strong suspicion
of histoplasmosis or parasitic infection (such as malaria
and trypanosomiasis) was never conﬁrmed. Antifungal
treatment was administered, with no clinical response. New
clinical signs appeared, including palpable lymph nodes,
mild hepatosplenomegaly, hematuria, and bruises on the
abdomen. The patient developed acute respiratory distress
syndrome (ARDS) and was transferred to the Intensive Care
Unit (ICU), where he died of acute pulmonary edema.
2.2.2. Morphology. Almost 3% atypical cells were detected
in blood and bone marrow (large- and medium-sized cells
with nucleoli and basophilic, vacuolated cytoplasm), with
hemophagocytosis.
2.2.3. FC. Immunophenotypic analysis of bone marrow
aspirate detected a T-cell population, CD3+, TCRab+,
CD8+, CD7+, brightly positive for cCD3 but CD10 and Tdt
negative. It revealed a restricted expansion of TCRVb13.2
region, but was also highly mitotic (Ki-67 = 40%), ki-
1/CD30+, EMA+, and ALK- (Figure 1). B- and NK- markers
were negative (Table 2).
2.2.4. IHC. IHC and immunocytochemical analysis of the
ﬁrst bone marrow biopsy was inadequate to provide a con-
clusion, despite the presence of histiocytes and hemophago-
cytosis. The analysis of a second bone marrow aspirate
documented inﬁltration (6-7%) by a peripheral highly
aggressive T-NHL, CD8+, CD30+ population.
2.2.5. Outcome. The patient died shortly after the diagnosis
was made on IHC.Case Reports in Medicine 3
Table 1: The main clinical features and laboratory results.
Case 1 Case 2 Case 3
Clinical features
F e v e r +++
Hepatosplenomegaly + + +
Lymphadenopathy + + +
W e a k n e s s +++
Weight loss − + −
DIC signs −−+
Swellings −−+
Pleural eﬀusion + + +
Hepatic failure + − +
R e n a l f a i l u r e +++
Laboratory ﬁndings
hemoglobin (Hb) ↓↓↓
platelets (PLTs) ↓↓↓
White blood cells (WBCs) ↑↑↓
C-reactive protein (CRP) ↑↑↑
Erythrocyte sedimentation rate (ESR) ↑↑∼
Lactate dehydrogenase (LDH) ↑↑↑
β2-microglobulin ↑↑↑
Ferritin ↑↑↑
d-dimers −↑∼
CMV, EBV, Parvo-B19, herpes viruses and Coxsackie B1-B6 −−−
Hepatitis-B virus (HBV) − + −
Hepatitis-C virus (HCV) −−−
Human immunodeﬁciency virus (HIV) −−−
Human T-lymphotropic viruses (HTLV-I, -II) −−−
Syphilis (VDRL) −−−
Brucella −−N
Toxoplasma −−−
Chlamydia pn. −−N
Yersinia, Listeria − N −
Leptospira − N −
Legionella, Pneumococcus urine antigens N − N
Bartonella − N −
Histoplasma N − N
Malaria N − N
Leishmania N −−
Other parasitic infections − N −
Rickettsiae N −−
M. tuberculosis − N −
CSF − NN
↑:in cr ease,↓:decrease,+: positive, ∼: not stable, NS: no signiﬁcant alteration,N: not evaluated, DIC: disseminatedintravascularcoagulation, VDRL: Venereal
Disease Research Laboratory test.
2.3. Case 3
2.3.1. Clinical Course. A 26-year-old female was admitted
with a febrile disease of 40-day duration, with increasing fa-
tigue and development of swellings all over her body. Hepat-
osplenomegaly and lymphadenopathy, small pericardial and
pleural eﬀusions, and renal failure and hepatic failure were
observed, and anemia, thrombocytopenia, and increased C-
reactive protein (CRP) were detected, all indicative of an
infectious etiology. There was a strong suspicion of human
zoonoses, but the microbiological and immunological inves-
tigation was inconclusive (Table 1). FC from a lymph node
processed at the time of admission provided diagnostic evi-
dence of HL. Lymph node IHC later veriﬁed the FC ﬁndings.4 Case Reports in Medicine
Table 2: Immunophenotype of atypical cell populations.
Case 1 Case 2
PB LN BM, PB
Atypical lymphocytes T (31%∗) T (30.5%∗)T 8 ( 3 % ∗)
CD3 1% 1% 100%
cCD3 100% 100% 100%
CD4 100% 100% 0%
CD8 1% 1% 100%
CD2 100% N 5%
CD7 35% 54% 95%
CD5 9% 8% 3%
TCRαβ 0.4% 0.5% 100%
TCRγδ 0.5% 0.5% 0%
Tdt 1% N 0%
CD34 1% N 0%
CD30(Ki-1) 55% 79.5% 41%
EMA 47% 30% 80%
CD15 3% 6% 2%
ALK N N 0%
CD10 0% N 0%
CD19 0% N 0%
CD20 0% N 0%
CD16 1.3% N 0%
CD56 1% N 0%
HLA-DR 78% N N
CD25 5% 15% N
CD14 0% N 0%
Ki-67 3% 22.6% 40%
CD45R0 100% N N
CD45RA 0.7% N N
PB: peripheral blood, BM: bone marrow, LN: lymph node, c: cytoplasmic, N: not evaluated, ∗(%) of total nucleated cells, while all other percentages refer to
the atypical cell populations.
2.3.2. Morphology. The processing of a lymph node section
revealed a small number of Hodgkin-like cells, among small-
andmedium-sized lymphocyteswithmaturechromatin. The
presence of monocytes with rare bilobed morphology, was
supportive of a CD30+ anaplastic lymphoma, while the BM
smear revealed hemophagocytosis. The morphological eval-
uation could not conﬁrm Reed-Sternberg (RS) morphology.
2.3.3. FC. Lymph node tissue section and pleural eﬀusion
were analyzed by FC. In the lymph node, the lymphocytes
(90% of total cells) were mature cells, including 55% T
(CD3+) and 33% B (CD19+). There was a predominant
T4 population, but also T8 cells and polyclonal B-cells
were detected. A nonhematolymphoid neoplastic cell pop-
ulation was excluded in the pleural eﬀusion (cytokeratin,
EMA, and BerEP4 negative). Classical HL was suggested
by the lymph node ﬁndings, because of the composite
immunophenotype CD45+/CD30+/CD71+/CD3+/CD20−,
in a high forward-scattered cell population (Figure 2), with
CD15dim expression. The FC conclusions were based also
on the morphological suspicion of Hodgkin and RS (HRS)
cells, particularly in the pleural eﬀusion (Figure 3). TCRγδ
lymphocytes were not detected in the lymph node, so
the possibility of a hepatosplenic TCRγδ-lymphoma was
eliminated.
2.3.4. IHC. IHC processing of an inﬁltrated axillary lymph
node provided the diagnosis of classical HL, although there
had been strong suspicion of NHL, because of certain
featuresoverlappingwiththoseofT-anaplastic largecelllym-
phoma (ALCL), or angioimmunoblastic T-cell lymphoma
(AITL). Such ﬁndings were the growth pattern (sinusoidal),
the hemophagocytic syndrome, the abundance of malignant
cells, and the diﬃculty in classifying the entity into an
HL subtype (“grey-zone” lymphoma). The IHC diagnosis
was based on the low coexpression of CD15 with CD30 in
neoplastic cells, togetherwith the ﬁndings of Pax-5+, MUM-
1+, Oct-2−,L C A −,E M A −,C D 2 0 −,C D 4 −,C D 5 6 −,a n d
Granzyme-B−. Investigation for ALK protein and Epstein-
Barr (EB) protein (LMP-1) was negative.Case Reports in Medicine 5
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Figure 1: Flow cytometry of the bone marrow and peripheral blood of patient 2, showing a monoclonal TCR Vβ13.2 T-cell population,
CD3+, TCRαβ+, CD8+, CD7+, CD30+, EMA+, ALK−, of high mitotic index (Ki-67 = 40%).
2.3.5. Outcome. Bleo-CHOP therapy was started two days
after admission, as there was no certain diagnosis of HL
apart from the FC ﬁndings. This was followed by the ABVD
regimen, based on the deﬁnitive diagnosis of classical HL
established by IHC. A complete remission was achieved
initially, followed by relapse and death 6 months later.
3.Materialsand Methods
3.1. FC. FC was performed on cell suspensions from periph-
eral blood,bone marrow aspirate, orfresh lymph node tissue
using previously described methods [5]. Brieﬂy, after a 15-
minute incubation of a suspension of cells labeled with
ﬂuorescent antibodies (10μL, undiluted) at room tempera-
ture, cells were thoroughly lysed (VersaLyse Lysing Solution,
OITest-3FixativeSolution,BeckmanCoulter)for10minutes
and centrifuged (1800rpm, 5 minutes). The supernatant
liquid was discarded, and the cells were resuspended in
0.5ml of PBS for analysis. For combined cell surface (s) and
cytoplasmic (c) immunophenotyping, cells were incubated
for 15 minutes with surface-reactive labeled antibodies,
followed by a second 15-minute incubation with 100μLF i x
& Permreagent“A”and thenwashed once.Aftertheaddition
of 100μL Fix & Perm reagent “B”, cells were incubated for
15 minutes with antibodies to cytoplasmic antigens, washed,
a n da n a l y z e do nt h ec y t o m e t e r .T h eF i x&P e r mr e a g e n tk i t
(Caltag Laboratories, San Francisco, CA, USA) was used for
cell ﬁxation and permeabilization. Tissue specimens were
mincedin3-4mLofPBSusingascalpel.Tissue homogenates
were used for touch imprints, which were stained with
May-Grunwald/Giemsa, followed by the preparation of sin-
gle-cell suspensions by ﬁltering through 100-μmﬁ l t e r s .F C
analysis was performed on a 5-color ﬂow cytometer, FC500
(Beckman Coulter). Analysis was made with CXP software
(BeckmanCoulter’s),and atleast 20,000eventswerecounted
for each sample.
The ﬂuorochrome combinations used included ﬂuores-
cein isothiocyanate (FITC), phycoerythrin (PE), PE-Texas
red (ECD), PE-cyanine (Cy)-5 (PC5), and PE-Cy7 (PC7).
The ﬂuorescently labeled antibodies were obtained from
Beckman Coulter and DakoCytomation, and includedIgG1-
FITC, IgG1-PE, CD3-FITC/PE/ECD/PC5, CD19-PC7,
CD20-PE/ECD/PC7, CD45-ECD/PC5, kappa-FITC, lamb-
da-PE, Tdt-FITC, bcl2-FITC, CD5-FITC/PC5, CD79a-PE,
CD38-FITC/PC5,BB4-PE, CD10-PE, EMA-FITC, CD30(Ki-
1)-FITC, CD15-FITC, HLA-DR-PE, Ki-67-FITC, IgM-FITC,
CD4-PE/PC7, CD8-FITC/PC5, CD2-FITC, CD7-FITC,
CD1a-FITC, CD14-FITC/PC7, ALK-FITC, CD16-FITC/PE/
PC5, CD56-PE/PC7, CD71-PE, TCRαβ-PE, TCRγδ-FITC,
CD25-PE, cytokeratin-FITC, CD45RO-FITC, and CD45RA-
PE. Appropriate isotype controls were used. FC analysis of
TCR-Vβ expression was performed with the IOTest Beta
Mark TCR-Vβ Repertoire kit (Beckman Coulter, Miami,
FL), as previously described [6]. For investigating the
possibility of HL (in Case 3), cells with high forward scatter
characteristics, which coexpressed CD71 and CD30, were
examined for B-(CD20) and T-cell markers (CD3), based
on the observation of T-cell rosetting around HRS cells,
as previously proposed [7]. The ﬁnal report was always
combined with morphology and clinical features.6 Case Reports in Medicine
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Figure 2: Flow cytometry of sample from the lymph node of patient 3. The coexpression of CD30 and CD71, in a CD45 and CD3 positive
population of high forward scatter characteristics, indicated the possibility of Hodgkin and Reed Sternberg (HRS) cells, based on T cell
rosetting around HRS cells. This composite immunophenotype (CD45+/CD30+/CD71+/CD3+/CD20−) (gate HD) was considered due to
contributions by the HRS cells and the surrounding T cells.
Figure 3: Microscopy of pleural eﬀusion specimen from patient 3
showing Hodgkin-like cells, surrounded by atypical lymphocytes,
probably T-cells (HRS-cell-T-cell rosette).
3.2. IHC and Immunocytochemical Analysis. Bone marrow
biopsiesand lymph node tissue sections were studiedby IHC
and immunocytochemistry. Immunostaining was carried
out in 4-μm formalin-ﬁxed and paraﬃn embedded sections.
Among the primary antibodies used were L26, CD79a,
CD3, CD2,UCHL1(T cells/CD45RO),MT1 (Tcells/CD43),
Anti-kappa, Anti-lambda, BerH2 (activated lymphocytes,
Hodgkin cells/CD30), LeuM1 (Hodgkin cells/CD15), CD5,
CD10, EMA, ALK, BOB1, Pax-5, Oct2, CD34, bcl2, bcl6,
CD23, ki-67, and KP1 (histiocytes/CD68), using an auto-
mated Envision/HPR technique (DAKO cytomation, Den-
mark). The ﬁnal diagnosis was made by two independent
observers, after the evaluation of morphological and ICH
ﬁndings in combination with the clinical data, without
knowledge of the FC results.
4.Discussion
Consensus has been reached on a list of clinical indications
for FC analysis [1], including patients with hepatospleno-
megaly and lymphadenopathy and/or atypical cells in the
blood or pleural eﬀusions, but the recommendations are toCase Reports in Medicine 7
ﬁrst rule out other possible causes of the clinical signs and
symptoms. There has been no evaluation of the utility of
FC in the initial investigation for life-threatening conditions,
suchasaggressivelymphomas,inseverelyillpatientswiththe
clinical picture of FUO. In order to highlight the potential
role of FC analysis in the critical care situation, we have
described three cases of lymphoma presenting as acute
infection, two of which were associated with HPS. The
aggressive clinical course of these cases demanded a rapid
initial assessment, in order to determine the diagnosis and
initiate appropriate treatment to try to ensure the survival
of the patients. All three cases were thoroughly investigated
for an underlying infection or autoimmune disease with
negative results, and FC was the only laboratory method to
provide early diagnostic evidence of lymphoma. The deﬁni-
tive diagnosis, obtained later by IHC, conﬁrmed the initial
FC ﬁndings. One patient (Case 2) died untreated, while
the other two patients (Cases 1 and 3) achieved remission,
despite critical delay in diagnosis.
AllthreecasespresentedasFUO,whileCases 2and3also
showed HPS. In cases of HPS and FUO, lymphoma entities
should be seriously considered in the diﬀerential diagnosis.
Severalcases ofB-and T-cell lymphoma associated with HPS
have been documented [8–16]. Tong et al. [17]h a v es u g -
gested that the median survival of patients with lymphoma
associated with HPS was much lower than that of those
with non-HPS associated lymphoma. It is apparent that
delay in the time-consuming procedure of the diﬀerential
diagnosis between infection, HPS-associated infection, and
HPS-associated lymphoma can signiﬁcantly increase the risk
of a fatal outcome.
FC provided early diagnostic evidence in all three cases,
althoughthe initiation ofappropriatetreatment wasdelayed,
pending the IHC conﬁrmation. In Case 1, the late immu-
nophenotyping of peripheral blood revealed the expression
of CD30 and EMA, with concurrent absence of CD15,
suggesting a Ki-1 anaplastic large-cell lymphoma, which
rarely presents with a leukemic picture and with large,
vacuolated basophilic cells. The awareness of a small-cell
variant [18] led to the study of a lymph node tissue sec-
tion, where the immunophenotype was compatible with T-
anaplastic lymphoma. FC investigation of CD25 expression
excluded the possibility of adult T-cell/leukemia/lymphoma,
and lymph node processing by IHC later conﬁrmed FC
results. In Case 2, the FC diagnosis was that of a T-anaplastic
l ym p h o m a ,K i - 1( C D3 0 )p o s i t i v e ,A L Kn e g a t i v e .T h es e c o n d ,
diagnostic, bone marrow biopsy documented the inﬁltration
by a highly aggressive peripheral T-NHL, CD8+, CD30+.
Unfortunately,the diagnosis cametoo lateas thepatient died
shortly after the histological report. In Case 3, although IHC
provided the ﬁnal diagnosis of HL, the possibility of a “grey-
zone” lymphoma had been previously discussed. FC had
earlier raised suspicions of HL, based on the morphological
features of HRS cells in the pleural ﬂuid, coupled with the
touch imprints.
Despite the limited documentation of the contribution
of FC to the diagnosis of HL, and in the absence of a stan-
dardized, well-accepted protocol, we based our FC approach
on the recently published paper by Fromm et al. [7, 19].
In their eﬀorts to identify HRS cells in lymph nodes, FC
assay revealed diagnostic sensitivity and speciﬁcity of 88.7%
and 100%, respectively [19]. HRS cells are often bound to T-
cells, typicallyshowing subsetsofHRScellswith andwithout
attached T cells (i.e., with or without rosette formation).
HRS-cell-T-cell rosetteshad a composite immunophenotype
(with antigen contribution from the T cells and the HRS
cells) when characterized by FC [7]. These investigations
were made with 10- [7] or 9-colour [19]ﬂ o wc y t o m e t r i c
assays, but with only 5-colour availability, we had to
modify our approach, which was based on the concept of
HRS-cell-T-cell rosette formation. The high forward scatter
characteristics and the T-cell immunophenotypic contribu-
tion of CD3 and CD45 bright expression, in association
with CD20 absence, in a CD30/CD71 positive, CD15dim
population was strongly supportive of HRS cells. The mor-
phological study of pleural eﬀusion supported our approach
(Figure 3).
The initial morphological and ICH diagnostic specu-
lations in Case 3 were partially based on familiar mor-
phological and immunophenotypic overlapping features. A
morphological and immunophenotypic overlap of ALCL
with classic HL has been recognized [20]. The expression
of ALK fusion proteins (chimeric ALK) has minimized the
diﬃculty in diﬀerentiation between ALCL and HL in cases
that lack expression of T-cell and B-cell antigens, but there
is still an overlap between ALK-negative ALCL and HL (e.g.,
CD15+/CD30+). It is clear that consensus histological and
IHC criteria for the diagnosis of ALK(−)A L C La r el a c k i n g
[21]. With regard to CD30 expression, the HRS cells of HL
and the neoplastic cells of ALCL both express CD30 [22],
which does not, however, have disease speciﬁcity, as it is an
activation-associated antigen [23–27].
Concisely, the cases we have presented concerned unu-
sual types of lymphoma, with rare clinical and laboratory
manifestations, mimicking FUO in patients severely ill but
also associated with secondary hemophagocytosis. Their
highly aggressive clinical course demanded a rapid and safe
diagnostic approach, to try to ensure survival, and in this
context, FC proved to provide a rapid diagnostic assess-
ment. Undoubtedly, IHC is the essential and most reliable
diagnostic tool and remains the gold standard of lymphoma
diagnosis; however, it is a tool which may involve diﬃcul-
ties, related to inadequate samples, diﬀerential diagnostic
problems, or critical delays, before the deﬁnitive diagnosis
is reached. Through the 3 cases described, we have tried to
highlight the potential of FC, combined with morphology,
as a valuable informative tool for the early assessment of
life-threatening conditions. We recommend that it should be
considered as an initial test in all undiagnosed cases of FUO
with organomegaly and/or atypical cells in blood or pleural
eﬀusion, in order to assess the possibility of an underlying
hematolymphoid neoplasm.
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